Annis ante vaccinatio immunotherapia contra morbum Parkinsonianum cogitatio utilis videbatur<ref>{{cite journal |authors=Schneeberger A., Mandler M., et al. |title=Vaccination for Parkinson's disease |journal=Parkinsonism & related disorders |year=2012 |month=Ian |volume=18 suppl |pages=S11-3 |url=https://pubmed.ncbi.nlm.nih.gov/22166404/}}</ref>. Anno 2020 [[vaccinatio]] nova cum immunotherapeutico ''PD01A'' proposita est<ref>{{cite journal |authors=Volc D., Poewe W., et al. |title=Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial |journal=The Lancet, neurology |year=2020 |month=Iul |volume=19 |issue=7 |pages=591-600 |url=https://pubmed.ncbi.nlm.nih.gov/32562684/}}</ref>, quo insunt ''affitopa'', [[alpha-synucleinum|alpha-synucleino]] similia (mimotopa) et simul imitatores [[epitopum|epitopi]] [[terminus C|termini C]], [[antigenum|antigena]] agunt. Mimotopa haec brevissima sunt, circiter longitudinis [[aminoacidum|aminoacidorum]] octo, ne [[cellula T|lymphocyti T]] stimulentur, attamen mimotopa per [[complexus histocompatibilitatis maior|complexus histocompatibilitatis maiores]] demonstrari possunt. Paulo post effectus immunotherapeutici ''PD03A'' divulgati sunt, [[atrophia multorum systematum|atrophiae multorum systematum]], aliae synucleopathiae<ref>{{cite journal ||authors=Meissner W. G., Pavy-Le Traon A., et al. |title=A Phase 1 Randomized Trial of Specific Active α-Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy |journal=Movement disorders |year=2020 |month=Nov |volume=35 |issue=11 |pages=1957-65 |url=https://pubmed.ncbi.nlm.nih.gov/32882100/}}</ref>. Ambo studia ad [[phases scientiae cliniace|phasem 1 scientiae clinicae]] referunt.
